LifeArc Ventures invests in Maxion Therapeutics
Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
LifeArc celebrates this year's UN Day for Women and Girls in STEM.
LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, provides an update on its portfolio.
LifeArc, Motor Neurone Disease Association and My Name’5 Doddie Foundation jointly award £1 million to progress development…
The first of RQ Bio's discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients has entered clinical trials.
LifeArc’s Chief Scientific Officer Dr Dave Powell comments on news that lecanemab has received regulatory and safety approval from the FDA.
Dave Powell on why LifeArc is evolving the way we do our science – and the difference we hope it will make to people’s lives.
We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.
Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.